Mallinckrodt reports positive phase 3 results from confirm study of terlipressin

Mallinckrodt presents positive phase 3 results from its confirm study of terlipressin in patients with hepatorenal syndrome type 1 (hrs-1) at the liver meeting® 2019.study showed a statistically significant number of patients on terlipressin achieved primary endpoint of verified hrs reversal versus placebo.plans to submit a new drug application for hrs-1 to u.s. fda in first half of 2020.
MNK Ratings Summary
MNK Quant Ranking